文献速递乳腺癌

在随机MONALEESA-2、-3和-7试验中,瑞博西利联合内分泌治疗HR+/HER2-晚期乳腺癌年轻至老年年龄组的疗效、安全性和患者报告结局

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
PubMed 文献 · Eur J Cancer · 2025-01-08

该分析汇总MONALEESA-2、-3和-7三项随机试验中1229例接受一线治疗的HR+/HER2-晚期乳腺癌患者,按年龄<65岁、65-74岁和≥75岁分组。无论年龄,瑞博西利联合内分泌治疗均显示一致的PFS和OS获益并延迟至首次化疗时间;安全性总体与总人群一致,≥75岁患者因不良事件停药率数值更高,患者报告结局在疼痛和疲乏评分方面各年龄组均观察到获益。

要点

  • 汇总1229例患者,63%为<65岁、27%为65-74岁、10%为≥75岁。
  • 无论年龄,瑞博西利联合内分泌治疗均显示一致的PFS和OS获益并延迟至首次化疗时间。
  • ≥75岁患者因不良事件停药率数值更高,且停药前未减量的比例更高。

核心结论

  • 该分析表明瑞博西利联合内分泌治疗对包括老年患者在内的所有年龄组HR+/HER2-晚期乳腺癌患者是有效且耐受良好的治疗。

研究设计与样本

  • 汇总MONALEESA-2、-3和-7三项随机试验中接受一线治疗的绝经前和绝经后HR+/HER2-晚期乳腺癌患者数据,按年龄<65岁、65-74岁和≥75岁分组分析。

主要发现

  • 共纳入1229例患者,<65岁占63%、65-74岁占27%、≥75岁占10%,基线特征总体均衡。
  • 无论患者年龄,瑞博西利联合内分泌治疗均显示一致的PFS和OS获益并延迟至首次化疗时间。
  • 瑞博西利联合内分泌治疗时最常见的首次后续治疗为内分泌治疗。
  • 安全性结果与总试验人群一致,未发现新信号;≥75岁患者因不良事件停药率数值更高,因不良事件停药者中≥75岁未预先减量的比例更高。
  • 所有年龄组中,瑞博西利联合内分泌治疗在疼痛和疲乏评分方面均观察到患者报告结局获益。

临床怎么用

  • 作者认为瑞博西利联合内分泌治疗对包括老年患者在内的所有年龄组HR+/HER2-晚期乳腺癌患者是有效且耐受良好的治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ribociclib + endocrine therapy (ET) showed significant progression-free survival (PFS) and overall survival (OS) benefits in the MONALEESA trials in patients with HR+ /HER2 - advanced breast cancer (ABC). We report efficacy, safety, and patient-reported outcomes (PROs) across age groups, including older patients, in these trials. METHODS: Data from the MONALEESA-2, -3, and -7 trials for pre- and postmenopausal patients receiving first-line treatment for ABC were pooled and analyzed by age (<65y, 65-74y, and ≥75y). PFS, OS, time to first chemotherapy (TTC), and time to definitive deterioration (TTD) in PROs were evaluated using Kaplan-Meier methods; a Cox regression model stratified by study and liver/lung metastasis was used for hazard ratios. RESULTS: Among 1229 patients included, 63 % were < 65y, 27 % were 65-74y, and 10 % were ≥ 75y. Baseline characteristics were generally well balanced. Regardless of patient age, ribociclib+ET showed a consistent PFS and OS benefit and delayed TTC. With ribociclib+ET, the most common first subsequent treatment was ET. Safety results were consistent with those in the overall trial population; no new signals were identified. Rates of discontinuation due to AEs with ribociclib+ET were numerically higher in patients ≥ 75y. Among patients who discontinued treatment due to AEs, the percentage without prior dose reduction was higher in those ≥ 75y. A PRO benefit with ribociclib+ET was observed across all age groups for pain and fatigue scores. CONCLUSIONS: This analysis demonstrated that ribociclib+ET is an effective and well-tolerated treatment for patients of all age groups with HR+ /HER2 - ABC, including older patients. (MONALEESA-2, NCT01958021; MONALEESA-3, NCT02422615; MONALEESA-7, NCT02278120).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hart LL, Im SA, Tolaney SM, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. Eur J Cancer. 2025. PMID: 39826197. doi:10.1016/j.ejca.2025.115225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。